Company Profile For Bavarian Nordic A/S

Bavarian Nordic A/S (BAVA.CO) (Copenhagen Stock Exchange)

sector: Healthcare · industry: Biotechnology ·

As of 26 Nov 2009

161.50DKK

Price Change

-4.50

Percent Change

-2.71%

Analyst Recommendations

Overview

Bavarian Nordic A/S is a Denmark-based company active within the biopharmaceutical sector. The Company is primarily engaged in the development, production and marketing of vaccines against infectious and life-threatening diseases. Its business strategy focuses on three areas: Biodefense, Cancer and Infectious Diseases. Its product pipeline includes seven development programs, namely Smallpox (IMVAMUNE) and Anthrax in the Biodefense area; PROSTVAC, Prostate (MVA-BN PRO) and Breast (MVA-BN HER2) in the Cancer area, and HIV multiantigen and Measles/RSV in the Infectious Diseases area. The majority of programs are based on the Company’s patented technology MVA-BN. The Company has ongoing clinical programs in human immunodeficiency virus (HIV) and smallpox, as well as pre-clinical and research programs in a number of infectious diseases.

Quick Financial Synopsis

BRIEF: For the six months ended 30 June 2009, Bavarian Nordic A/S's revenue increased 43% to DKR32.9M. Net loss for the period increased 56% to DK146.2M. Revenue reflects an increase in demand for the Company's products and services as well as favorable market conditions. Higher net loss reflects decreased gross margins as well as higher sales and administrative costs, and increased research and development expenses.